Asparaginase

Also known as: Colaspase

Active ingredient description

Asparaginase hydrolyses asparagine to aspartic acid and ammonia. In contrast to normal cells, lymphoblastic tumour cells have a very limited capacity for synthesising asparagine because of a significantly reduced expression of asparagine synthetase. Therefore, they require asparagine which diffuses from the extracellular environment. As a result of asparaginase-induced asparagine depletion in serum, protein synthesis in lymphoblastic tumour cells is disturbed while sparing most normal cells.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Asparaginase
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX02

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country

Medicines

Asparaginase is the active ingredient of these drugs:

Drug
Countries

Austria Canada Estonia Netherlands Poland

United States

Estonia

Canada France

South Africa

Hong Kong Mexico Singapore

Austria Brazil Estonia France Ireland

Chemical formula: C₁₃₇₇H₂₂₀₈N₃₈₂O₄₄₂S₁₇

External identifiers

CAS Substance: 9015-68-3
DrugBank Drug: DB00023
KEGG Drug: D02997
PubChem Compound: 5460875
RxNorm Ingredient: 1156
SNOMED-CT Concept: 18780003
Asparaginase (substance)
SNOMED-CT Concept: 371014004
Asparaginase (substance)
UNII Identifier: G4FQ3CKY5R
ASPARAGINASE